Why Patients Don't Always Tell Sponsors First

Patients and families participating in a clinical trial may not always raise concerns with the sponsor or site when they first come up. Even when guidance is clear and support is available, they may worry that disclosing side effects, non-compliance, or participation challenges could put their place in the study at risk.

In this short webinar excerpt, Karsten Baumgaertel explains why patient advocacy groups can become the first place those concerns surface — a reminder that trust is not a soft benefit in clinical research, but part of how study teams learn what formal trial channels may miss.